Accredited Investors Inc. Grows Stock Holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Accredited Investors Inc. lifted its stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 44.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,000 shares of the company’s stock after purchasing an additional 31,000 shares during the period. Accredited Investors Inc.’s holdings in Treace Medical Concepts were worth $744,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in TMCI. Charles Schwab Investment Management Inc. boosted its stake in shares of Treace Medical Concepts by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 391,033 shares of the company’s stock valued at $2,268,000 after purchasing an additional 17,783 shares during the period. FMR LLC grew its position in Treace Medical Concepts by 228.5% during the third quarter. FMR LLC now owns 78,135 shares of the company’s stock valued at $453,000 after purchasing an additional 54,353 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Treace Medical Concepts in the 3rd quarter valued at $75,000. Verition Fund Management LLC grew its holdings in Treace Medical Concepts by 10.6% in the 3rd quarter. Verition Fund Management LLC now owns 88,370 shares of the company’s stock valued at $513,000 after buying an additional 8,468 shares during the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of Treace Medical Concepts during the 3rd quarter worth about $58,000. 84.08% of the stock is owned by institutional investors and hedge funds.

Treace Medical Concepts Trading Down 1.9 %

Shares of Treace Medical Concepts stock opened at $7.27 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.12 and a quick ratio of 2.98. The firm has a fifty day moving average price of $8.86 and a 200 day moving average price of $7.73. The stock has a market cap of $457.21 million, a PE ratio of -7.34 and a beta of 0.77. Treace Medical Concepts, Inc. has a 1 year low of $3.92 and a 1 year high of $12.65.

Insider Buying and Selling at Treace Medical Concepts

In other Treace Medical Concepts news, insider Sean F. Scanlan sold 50,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $7.97, for a total value of $398,500.00. Following the transaction, the insider now directly owns 364,081 shares of the company’s stock, valued at $2,901,725.57. This trade represents a 12.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 24.43% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently commented on TMCI. Lake Street Capital started coverage on Treace Medical Concepts in a report on Tuesday, December 31st. They issued a “buy” rating and a $14.50 price objective for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $8.00 price objective on shares of Treace Medical Concepts in a research note on Tuesday, December 17th. Truist Financial dropped their price target on shares of Treace Medical Concepts from $10.00 to $9.50 and set a “hold” rating on the stock in a research report on Thursday, March 13th. Finally, BTIG Research raised Treace Medical Concepts from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Tuesday, February 4th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Treace Medical Concepts currently has an average rating of “Hold” and an average price target of $10.14.

Treace Medical Concepts Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.